Search
X4 Pharmaceuticals Inc
XFORAdd to Watchlist
3.300USD
-0.050-1.49%
Market hours 11/03, 11:31（ET）
327.19MMarket Cap
LossP/E TTM
X4 Pharmaceuticals Inc (XFOR) Stock Price Target & Forecast
Analyst Rating
Based on 5 analysts giving stock ratings to X4 Pharmaceuticals Inc in the past month.
Strong Buy
3 Strong Buy
2 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
11.600USD+246.27%
XFOR Analyst Recommendation Trends
In the current month, XFOR has received 2 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. XFOR average Analyst price target in the last month is 11.600.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
3
3
3
3
3
2
2
2
2
2
2
2
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5
5
5
5
4
3
3
3
XFOR Analyst Rating for Peer Comparison
Updated: Nov 1, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Biogen Inc
BIIB
10
17
10
1
0
38
Amgen Inc
AMGN
4
9
19
3
1
36
Eli Lilly and Co
LLY
10
19
3
1
0
33
Vertex Pharmaceuticals Inc
VRTX
10
17
5
0
1
33
Alnylam Pharmaceuticals Inc
ALNY
5
18
9
0
0
32
AbbVie Inc
ABBV
8
18
6
0
0
32
Merck & Co Inc
MRK
7
15
9
0
0
31
Neurocrine Biosciences Inc
NBIX
13
14
4
0
0
31
Gilead Sciences Inc
GILD
7
18
5
0
0
30
Bristol-Myers Squibb Co
BMY
5
6
18
1
0
30
Financial Forecasting
Based on analysts' estimates, XFOR EPS is projected to reach -0.186 in FY2026Q3, following reported EPS of -0.128 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.35
-0.20
-0.18
-0.19
-0.20
Actual
-0.26
-0.16
-0.13
--
--
Surprise
+24.26%
+19.86%
+28.96%
--
--
FAQs
What is X4 Pharmaceuticals Inc's expected revenue for the next quarter?
X4 Pharmaceuticals Inc's expected revenue is 2.30M.
What is X4 Pharmaceuticals Inc's price target?
Analysts forecast that X4 Pharmaceuticals Inc's price target is USD 11.60, with the highest forecast at USD 13.00 and the lowest forecast at USD 10.00.
How have X4 Pharmaceuticals IncXFOR's recent earnings per share performed?
The market expectation was USD -0.13, while X4 Pharmaceuticals IncXFOR's earnings per share (EPS) for the previous quarter was USD -0.16. EPS for the next quarter is expected at USD -0.19.
What is the analyst rating for X4 Pharmaceuticals Inc?
Based on the ratings of X4 Pharmaceuticals Inc's stock from 5 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.